Vera Therapeutics (NASDAQ:VERA) Stock Price Up 6.1%

Vera Therapeutics, Inc. (NASDAQ:VERAGet Rating) rose 6.1% during trading on Wednesday . The stock traded as high as $22.18 and last traded at $22.18. Approximately 3,592 shares traded hands during trading, a decline of 97% from the average daily volume of 109,798 shares. The stock had previously closed at $20.90.

Analysts Set New Price Targets

VERA has been the subject of several research analyst reports. JPMorgan Chase & Co. started coverage on Vera Therapeutics in a research note on Tuesday, July 12th. They set an “overweight” rating and a $35.00 target price for the company. HC Wainwright boosted their price target on Vera Therapeutics from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, August 22nd.

Vera Therapeutics Stock Down 1.8 %

The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 0.04. The company has a fifty day simple moving average of $19.21 and a two-hundred day simple moving average of $18.54.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 20,528 shares of Vera Therapeutics stock in a transaction on Friday, August 12th. The stock was sold at an average price of $20.16, for a total value of $413,844.48. Following the completion of the transaction, the chief executive officer now directly owns 137,400 shares of the company’s stock, valued at approximately $2,769,984. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Marshall Fordyce sold 20,528 shares of the business’s stock in a transaction on Friday, August 12th. The stock was sold at an average price of $20.16, for a total transaction of $413,844.48. Following the completion of the transaction, the chief executive officer now owns 137,400 shares of the company’s stock, valued at approximately $2,769,984. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Joanne Curley sold 9,104 shares of the business’s stock in a transaction on Thursday, July 14th. The stock was sold at an average price of $15.14, for a total value of $137,834.56. Following the transaction, the insider now directly owns 18,273 shares of the company’s stock, valued at approximately $276,653.22. The disclosure for this sale can be found here. Insiders sold 117,102 shares of company stock valued at $2,228,210 in the last three months. Corporate insiders own 43.10% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

A number of institutional investors have recently modified their holdings of the business. Amalgamated Bank acquired a new position in Vera Therapeutics in the 1st quarter worth about $34,000. UBS Group AG acquired a new position in Vera Therapeutics in the 1st quarter worth about $47,000. Legal & General Group Plc increased its holdings in Vera Therapeutics by 274.8% in the 2nd quarter. Legal & General Group Plc now owns 4,898 shares of the company’s stock worth $67,000 after purchasing an additional 3,591 shares in the last quarter. American International Group Inc. increased its holdings in Vera Therapeutics by 29.2% in the 1st quarter. American International Group Inc. now owns 6,794 shares of the company’s stock worth $160,000 after purchasing an additional 1,535 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new position in Vera Therapeutics in the 1st quarter worth about $209,000. Institutional investors and hedge funds own 85.24% of the company’s stock.

About Vera Therapeutics

(Get Rating)

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy.

Featured Stories

Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.